Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan

References

• Bywaters EG. Still's disease in the adult. Ann Rheum Dis. 1971; 30(2):121–33.
   PubMedGoogle Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424–30.
   PubMed Web of Science ®Google Scholar
• Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol. 1990;17(8):1058–63.
   PubMed Web of Science ®Google Scholar
• Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol. 1997: 7(4):221–5.
   PubMedGoogle Scholar
• Mitamura M, Tada Y, Koarada S, Inoue H, Suematsu R, Ohta A, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still's disease. Mod Rheumatol. 2009;19(1):57–63.
   PubMed Web of Science ®Google Scholar
• Puéchal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult still's disease. Arthritis Care Res. 2011;63(1):155–9.
   Google Scholar
• Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712–19.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2): 118–36.
   PubMed Web of Science ®Google Scholar
• White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30: 377–99.
   PubMed Web of Science ®Google Scholar
• Coffernils M, Soupart A, Pradier O, Feremans W, Nève P, Decaux G. Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndromes. J Rheumatol. 1992;19(9):1425.
   PubMedGoogle Scholar
• Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54(7):587–90.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol. 1996;14(6):653–5.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum. 2001;44(7):1716–7.
   PubMedGoogle Scholar
• Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, et al. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65(12):1596–601.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still disease. Manifestation, treatment, outcome, and prognostic factors in 57 patients. Midicine (Baltimore). 2014;93(2):91–99.
   PubMedGoogle Scholar
• Elcon KB, Hughes GR, Bywaters EG, Ryan PF, Inman RD, Bowley NB, et al. Adult-onset Still's disease. Twenty-year followup and further studies of patients with active disease. Arthritis Rheum. 1982;25(6):647–54.
   PubMedGoogle Scholar
• Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A, Pezzutto A. Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis. 1992;51(5):683–5.
   PubMedGoogle Scholar
• Akritidis N, Giannakakis I, Giouglis T. Ferritin levels and response to treatment in patients with adult Still's disease. J Rheumatol. 1996;23(1):201–2.
   PubMedGoogle Scholar
• de Boysson H, Février J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol. 2013;32(1):141–7.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olivé A, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014; 66(6):1659–65.
   PubMed Web of Science ®Google Scholar
• Bannai E, Yamashita H, Kaneko S, Ueda Y, Ozaki T, Tsuchiya H, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol. 2014 Apr 3. [Epub ahead of print].
   Google Scholar
• Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–6.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014; 41(4):759–67.
   PubMedGoogle Scholar